Eli Lilly\'s next-generation obesity drug candidate retatrutide showed an average 25 percent weight loss at the highest dose after 80 weeks in a Phase 3 trial. Among participants who extended treatment to 104 weeks, average weight loss rose to 30 percent. Results were published in the New England Journal of Medicine, with more than one-third losing at least 30 percent of body weight. The study did not directly compare retatrutide with existing obesity drugs, and researchers said further trials are needed.

Tesla has set up a local unit in Vietnam, registering Tesla Motors Vietnam this month as it prepares to enter Southeast Asia’s largest electric vehicle market. Specific timing and business plans have not been disclosed. Local automaker VinFast dominates the market, supported by its charging and after-sales service network and an electric taxi affiliate. Analysts said Tesla may face challenges building distribution and service networks and proving charging convenience to consumers.